Skip to main content
Top
Published in: Current Treatment Options in Neurology 6/2010

01-11-2010 | Pediatric Neurology

Treatment of Tics and Tourette Syndrome

Author: Harvey S. Singer, MD

Published in: Current Treatment Options in Neurology | Issue 6/2010

Login to get access

Opinion statement

Tics come in a variety of types and frequencies; have a waxing and waning course; are exacerbated by stress, anxiety, and fatigue; and often resolve or improve in the teenage or early adult years. Tourette syndrome requires the presence of chronic, fluctuating motor and phonic tics. In addition to tics, individuals with Tourette syndrome often have a variety of comorbid conditions such as attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder, depression and anxiety, episodic outbursts, and academic difficulties. These conditions often are a greater source of difficulty than the tics themselves. All patients with tics should be evaluated to assure proper diagnosis and to identify any associated psychopathology or academic difficulty. The treatment of tics begins with education of the patient and family, including discussions about the fundamentals of tics: their characteristics, etiology, outcomes, and available treatments. Therapy should be individualized based on the extent of impairment, available support, ability to cope, and the presence of other problems. Indications for the treatment of tics include psychosocial problems (loss of self-esteem, comments from peers, excessive worries about tics, diminished participation in activities), functional difficulties, classroom disruption, and physical discomfort. A variety of behavioral approaches can be used. Recent studies have emphasized the value of comprehensive behavioral intervention for tics (CBIT). Because habit reversal is the major component of CBIT, a cooperative patient, the presence of a premonitory urge, and a committed family are essential ingredients for success. If tic-suppressing medication is required, a two-tier approach and monotherapy are recommended. First-tier medications, notably the α-adrenergic agonists, are recommended for individuals with milder tics, especially persons with both tics and ADHD. Second-tier medications include various typical and atypical neuroleptics. Their sequence of prescription is often based on physician experience; I favor pimozide and fluphenazine. Atypical antipsychotics, such as risperidone and aripiprazole, have some advantages based on their side-effect profile and are particularly beneficial in individuals with significant co-existing behavioral issues. As will become readily apparent, however, few medications have been adequately assessed. Deep brain stimulation is an emerging therapy, but further data are required to optimize the location of electrode placement and stimulation and to determine precise indications for its implementation. Stimulant medication is effective in treating ADHD in children with tics; studies reducing concerns about its use are discussed.
Literature
1.
go back to reference Singer HS: Tourette’s syndrome: from behaviour to biology. Lancet Neurol 2005, 4:149–159.PubMed Singer HS: Tourette’s syndrome: from behaviour to biology. Lancet Neurol 2005, 4:149–159.PubMed
2.•
go back to reference Walkup JT, Ferrao Y, Leckman JF, et al.: Tic disorders: some key issues for DSM-V. Depress Anxiety 2010, 27:600–610.CrossRefPubMed Walkup JT, Ferrao Y, Leckman JF, et al.: Tic disorders: some key issues for DSM-V. Depress Anxiety 2010, 27:600–610.CrossRefPubMed
3.
go back to reference Khalifa N, von Knorring AL: Tourette syndrome and other tic disorders in a total population of children: clinical assessment and background. Acta Paediatr 2005, 94:1608–1614.CrossRefPubMed Khalifa N, von Knorring AL: Tourette syndrome and other tic disorders in a total population of children: clinical assessment and background. Acta Paediatr 2005, 94:1608–1614.CrossRefPubMed
4.
go back to reference Kurlan R, Como PG, Miller B, et al.: The behavioral spectrum of tic disorders: a community-based study. Neurology 2002, 59:414–420.PubMed Kurlan R, Como PG, Miller B, et al.: The behavioral spectrum of tic disorders: a community-based study. Neurology 2002, 59:414–420.PubMed
5.
go back to reference Cavanna AE, Eddy C, Rickards HE: Cognitive functioning in Tourette syndrome. Discov Med 2009, 8:191–195.PubMed Cavanna AE, Eddy C, Rickards HE: Cognitive functioning in Tourette syndrome. Discov Med 2009, 8:191–195.PubMed
6.•
go back to reference Pringsheim T, Lang A, Kurlan R, et al.: Understanding disability in Tourette syndrome. Dev Med Child Neurol 2009, 51:468–472.CrossRefPubMed Pringsheim T, Lang A, Kurlan R, et al.: Understanding disability in Tourette syndrome. Dev Med Child Neurol 2009, 51:468–472.CrossRefPubMed
7.
go back to reference Mejia NI, Jankovic J: Secondary tics and tourettism. Rev Bras Psiquiatr 2005, 27:11–17.PubMed Mejia NI, Jankovic J: Secondary tics and tourettism. Rev Bras Psiquiatr 2005, 27:11–17.PubMed
8.
go back to reference Bergin A, Waranch HR, Brown J, et al.: Relaxation therapy in Tourette syndrome: a pilot study. Pediatr Neurol 1998, 18:136–142.CrossRefPubMed Bergin A, Waranch HR, Brown J, et al.: Relaxation therapy in Tourette syndrome: a pilot study. Pediatr Neurol 1998, 18:136–142.CrossRefPubMed
9.
go back to reference O’Connor KP, Laverdure A, Taillon A, et al.: Cognitive behavioral management of Tourette’s syndrome and chronic tic disorder in medicated and unmedicated samples. Behav Res Ther 2009, 47:1090–1095.CrossRefPubMed O’Connor KP, Laverdure A, Taillon A, et al.: Cognitive behavioral management of Tourette’s syndrome and chronic tic disorder in medicated and unmedicated samples. Behav Res Ther 2009, 47:1090–1095.CrossRefPubMed
10.
go back to reference Woods DW, Piacentini JC, Chang SW, et al.: Managing Tourette Syndrome: A Behavioral Intervention for Children and Adults. New York: Oxford University Press; 2008. Woods DW, Piacentini JC, Chang SW, et al.: Managing Tourette Syndrome: A Behavioral Intervention for Children and Adults. New York: Oxford University Press; 2008. Woods DW, Piacentini JC, Chang SW, et al.: Managing Tourette Syndrome: A Behavioral Intervention for Children and Adults. New York: Oxford University Press; 2008. Woods DW, Piacentini JC, Chang SW, et al.: Managing Tourette Syndrome: A Behavioral Intervention for Children and Adults. New York: Oxford University Press; 2008.
11.
go back to reference Himle MB, Woods DW, Piacentini JC, Walkup JT: Brief review of habit reversal training for Tourette syndrome. J Child Neurol 2006, 21:719–725.CrossRefPubMed Himle MB, Woods DW, Piacentini JC, Walkup JT: Brief review of habit reversal training for Tourette syndrome. J Child Neurol 2006, 21:719–725.CrossRefPubMed
12.
go back to reference Deckersbach T, Rauch S, Buhlmann U, Wilhelm S: Habit reversal versus supportive psychotherapy in Tourette’s disorder: a randomized controlled trial and predictors of treatment response. Behav Res Ther 2006, 44:1079–1090.CrossRefPubMed Deckersbach T, Rauch S, Buhlmann U, Wilhelm S: Habit reversal versus supportive psychotherapy in Tourette’s disorder: a randomized controlled trial and predictors of treatment response. Behav Res Ther 2006, 44:1079–1090.CrossRefPubMed
13.••
go back to reference Piacentini J, Woods DW, Scahill L, et al.: Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA 2010, 303:1929–1937.CrossRefPubMed Piacentini J, Woods DW, Scahill L, et al.: Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA 2010, 303:1929–1937.CrossRefPubMed
14.
go back to reference Garcia-Lopez R, Romero-Gonzalez J, Perea-Milla E, et al.: [An open study evaluating the efficacy and security of magnesium and vitamin B(6) as a treatment of Tourette syndrome in children.]. Med Clin (Barc) 2008, 131:689–692.CrossRef Garcia-Lopez R, Romero-Gonzalez J, Perea-Milla E, et al.: [An open study evaluating the efficacy and security of magnesium and vitamin B(6) as a treatment of Tourette syndrome in children.]. Med Clin (Barc) 2008, 131:689–692.CrossRef
15.
go back to reference Ma S, Liu XY, Yu RL, Chen LJ: [Clinical observation on acupuncture for treatment of Tourette’s syndrome]. Zhongguo Zhen Jiu 2006, 26:392–394.PubMed Ma S, Liu XY, Yu RL, Chen LJ: [Clinical observation on acupuncture for treatment of Tourette’s syndrome]. Zhongguo Zhen Jiu 2006, 26:392–394.PubMed
16.
go back to reference Mantovani A, Lisanby SH, Pieraccini F, et al.: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette’s syndrome (TS). Int J Neuropsychopharmacol 2006, 9:95–100.CrossRefPubMed Mantovani A, Lisanby SH, Pieraccini F, et al.: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette’s syndrome (TS). Int J Neuropsychopharmacol 2006, 9:95–100.CrossRefPubMed
17.
go back to reference Mantovani A, Leckman JF, Grantz H, et al.: Repetitive transcranial magnetic stimulation of the supplementary motor area in the treatment of Tourette syndrome: report of two cases. Clin Neurophysiol 2007, 118:2314–2315.CrossRefPubMed Mantovani A, Leckman JF, Grantz H, et al.: Repetitive transcranial magnetic stimulation of the supplementary motor area in the treatment of Tourette syndrome: report of two cases. Clin Neurophysiol 2007, 118:2314–2315.CrossRefPubMed
18.••
go back to reference Scahill L, Erenberg G, Berlin CM Jr, et al.: Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006, 3:192–206.CrossRefPubMed Scahill L, Erenberg G, Berlin CM Jr, et al.: Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006, 3:192–206.CrossRefPubMed
19.•
go back to reference Tourette's Syndrome Study Group: Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002, 58:527–536. Tourette's Syndrome Study Group: Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002, 58:527–536.
20.
go back to reference Hedderick EF, Morris CM, Singer HS: Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 2009, 40:420–425.CrossRefPubMed Hedderick EF, Morris CM, Singer HS: Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 2009, 40:420–425.CrossRefPubMed
21.
go back to reference Gaffney GR, Perry PJ, Lund BC, et al.: Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 2002, 41:330–336.CrossRefPubMed Gaffney GR, Perry PJ, Lund BC, et al.: Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 2002, 41:330–336.CrossRefPubMed
22.
go back to reference Du YS, Li HF, Vance A, et al.: Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust NZ J Psychiatry 2008, 42:807–813.CrossRef Du YS, Li HF, Vance A, et al.: Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust NZ J Psychiatry 2008, 42:807–813.CrossRef
23.•
go back to reference Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF: Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009, 48:884–893.CrossRefPubMed Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF: Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009, 48:884–893.CrossRefPubMed
24.
go back to reference Scahill L, Chappell PB, Kim YS, et al.: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001, 158:1067–1074.CrossRefPubMed Scahill L, Chappell PB, Kim YS, et al.: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001, 158:1067–1074.CrossRefPubMed
25.
go back to reference Cummings DD, Singer HS, Krieger M, et al.: Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 2002, 25:325–332.CrossRefPubMed Cummings DD, Singer HS, Krieger M, et al.: Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 2002, 25:325–332.CrossRefPubMed
26.
go back to reference Abuzzahab FS, Brown VL: Control of Tourette’s syndrome with topiramate. Am J Psychiatry 2001, 158:968.PubMed Abuzzahab FS, Brown VL: Control of Tourette’s syndrome with topiramate. Am J Psychiatry 2001, 158:968.PubMed
27.
go back to reference Kuo SH, Jimenez-Shahed J: Topiramate in treatment of Tourette syndrome. Clin Neuropharmacol 2010, 33:32–34.CrossRefPubMed Kuo SH, Jimenez-Shahed J: Topiramate in treatment of Tourette syndrome. Clin Neuropharmacol 2010, 33:32–34.CrossRefPubMed
28.
go back to reference Jankovic J, Jimenez-Shahed J, Brown LW: A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2009, 81:70–73.CrossRefPubMed Jankovic J, Jimenez-Shahed J, Brown LW: A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2009, 81:70–73.CrossRefPubMed
29.
go back to reference Awaad Y, Michon AM, Minarik S: Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 2005, 20:714–718.CrossRefPubMed Awaad Y, Michon AM, Minarik S: Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 2005, 20:714–718.CrossRefPubMed
30.
go back to reference Fernandez-Jaen A, Fernandez-Mayoralas DM, Munoz-Jareno N, Calleja-Perez B: An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. Eur J Paediatr Neurol 2009, 13:541–545.CrossRefPubMed Fernandez-Jaen A, Fernandez-Mayoralas DM, Munoz-Jareno N, Calleja-Perez B: An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. Eur J Paediatr Neurol 2009, 13:541–545.CrossRefPubMed
31.
go back to reference Smith-Hicks CL, Bridges DD, Paynter NP, Singer HS: A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord 2007, 22:1764–1770.CrossRefPubMed Smith-Hicks CL, Bridges DD, Paynter NP, Singer HS: A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord 2007, 22:1764–1770.CrossRefPubMed
32.
go back to reference Shapiro AK: Gilles de la Tourette Syndrome. New York: Raven; 1988. Shapiro AK: Gilles de la Tourette Syndrome. New York: Raven; 1988.
33.
34.
go back to reference Singer HS, Wendlandt J, Krieger M, Giuliano J: Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 2001, 56:599–604.PubMed Singer HS, Wendlandt J, Krieger M, Giuliano J: Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 2001, 56:599–604.PubMed
35.
go back to reference Drtilkova I, Balaotkova B, Lemanova H, Zak J: Therapeutical effects of clonidine and clonazepam in children with tic syndrome. Homeost Health Dis 1994, 35:296. Drtilkova I, Balaotkova B, Lemanova H, Zak J: Therapeutical effects of clonidine and clonazepam in children with tic syndrome. Homeost Health Dis 1994, 35:296.
36.••
go back to reference Ray WA, Chung CP, Murray KT, et al.: Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360:225–235.CrossRefPubMed Ray WA, Chung CP, Murray KT, et al.: Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360:225–235.CrossRefPubMed
37.
go back to reference Schneeweiss S, Avorn J: Antipsychotic agents and sudden cardiac death—How should we manage the risk? N Engl J Med 2009, 360:294–296.CrossRefPubMed Schneeweiss S, Avorn J: Antipsychotic agents and sudden cardiac death—How should we manage the risk? N Engl J Med 2009, 360:294–296.CrossRefPubMed
38.•
go back to reference Pringsheim T, Marras C: Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev 2009, CD006996. This comprehensive review of prior studies assessed the benefits and risks of pimozide in comparison to placebo or other medications in treating tics in Tourette syndrome. Pringsheim T, Marras C: Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev 2009, CD006996. This comprehensive review of prior studies assessed the benefits and risks of pimozide in comparison to placebo or other medications in treating tics in Tourette syndrome.
39.
go back to reference Singer HS, Gammon K, Quaskey S: Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 1985, 12:71–74.CrossRefPubMed Singer HS, Gammon K, Quaskey S: Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 1985, 12:71–74.CrossRefPubMed
40.
go back to reference Goetz CG, Tanner CM, Klawans HL: Fluphenazine and multifocal tic disorders. Arch Neurol 1984, 41:271–272.PubMed Goetz CG, Tanner CM, Klawans HL: Fluphenazine and multifocal tic disorders. Arch Neurol 1984, 41:271–272.PubMed
41.
42.
go back to reference Shapiro E, Shapiro AK, Fulop G, et al.: Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1989, 46:722–730.PubMed Shapiro E, Shapiro AK, Fulop G, et al.: Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1989, 46:722–730.PubMed
43.
go back to reference Scahill L, Leckman JF, Schultz RT, et al.: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60:1130–1135.CrossRefPubMed Scahill L, Leckman JF, Schultz RT, et al.: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60:1130–1135.CrossRefPubMed
44.
go back to reference Dion Y, Annable L, Sandor P, Chouinard G: Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002, 22:31–39.CrossRefPubMed Dion Y, Annable L, Sandor P, Chouinard G: Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002, 22:31–39.CrossRefPubMed
45.
go back to reference Bruggeman R, van der Linden C, Buitelaar JK, et al.: Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001, 62:50–56.CrossRefPubMed Bruggeman R, van der Linden C, Buitelaar JK, et al.: Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001, 62:50–56.CrossRefPubMed
46.
go back to reference Gilbert DL, Batterson JR, Sethuraman G, Sallee FR: Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004, 43:206–214.CrossRefPubMed Gilbert DL, Batterson JR, Sethuraman G, Sallee FR: Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004, 43:206–214.CrossRefPubMed
47.
go back to reference Budman C, Coffey BJ, Shechter R, et al.: Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008, 18:509–515.CrossRefPubMed Budman C, Coffey BJ, Shechter R, et al.: Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008, 18:509–515.CrossRefPubMed
48.
go back to reference Kawohl W, Schneider F, Vernaleken I, Neuner I: Chronic motor tic disorder and aripiprazole. J Neuropsychiatry Clin Neurosci 2009, 21:224.PubMed Kawohl W, Schneider F, Vernaleken I, Neuner I: Chronic motor tic disorder and aripiprazole. J Neuropsychiatry Clin Neurosci 2009, 21:224.PubMed
49.
go back to reference Murphy TK, Mutch PJ, Reid JM, et al.: Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol 2009, 19:441–447.CrossRefPubMed Murphy TK, Mutch PJ, Reid JM, et al.: Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol 2009, 19:441–447.CrossRefPubMed
50.
go back to reference Davies L, Stern JS, Agrawal N, Robertson MM: A case series of patients with Tourette’s syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006, 21:447–453.CrossRefPubMed Davies L, Stern JS, Agrawal N, Robertson MM: A case series of patients with Tourette’s syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006, 21:447–453.CrossRefPubMed
51.
go back to reference Seo WS, Sung HM, Sea HS, Bai DS: Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 2008, 18:197–205.CrossRefPubMed Seo WS, Sung HM, Sea HS, Bai DS: Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 2008, 18:197–205.CrossRefPubMed
52.
go back to reference Sallee FR, Kurlan R, Goetz CG, et al.: Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000, 39:292–299.CrossRefPubMed Sallee FR, Kurlan R, Goetz CG, et al.: Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000, 39:292–299.CrossRefPubMed
53.
go back to reference Willmund G, Lee AH, Wertenauer F, et al.: Vocal tics associated with ziprasidone. J Clin Psychopharmacol 2009, 29:611–612.CrossRefPubMed Willmund G, Lee AH, Wertenauer F, et al.: Vocal tics associated with ziprasidone. J Clin Psychopharmacol 2009, 29:611–612.CrossRefPubMed
54.
go back to reference Budman CL, Gayer A, Lesser M, et al.: An open-label study of the treatment efficacy of olanzapine for Tourette’s disorder. J Clin Psychiatry 2001, 62:290–294.CrossRefPubMed Budman CL, Gayer A, Lesser M, et al.: An open-label study of the treatment efficacy of olanzapine for Tourette’s disorder. J Clin Psychiatry 2001, 62:290–294.CrossRefPubMed
55.
go back to reference McCracken JT, Suddath R, Chang S, et al.: Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol 2008, 18:501–508.CrossRefPubMed McCracken JT, Suddath R, Chang S, et al.: Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol 2008, 18:501–508.CrossRefPubMed
56.
go back to reference Onofrj M, Paci C, D’Andreamatteo G, Toma L: Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 2000, 247:443–446.CrossRefPubMed Onofrj M, Paci C, D’Andreamatteo G, Toma L: Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 2000, 247:443–446.CrossRefPubMed
57.
go back to reference Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol 2003, 13:295–299.CrossRefPubMed Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol 2003, 13:295–299.CrossRefPubMed
58.
go back to reference Copur M, Arpaci B, Demir T, Narin H: Clinical effectiveness of quetiapine in children and adolescents with Tourette’s syndrome: a retrospective case-note survey. Clin Drug Investig 2007, 27:123–130.CrossRefPubMed Copur M, Arpaci B, Demir T, Narin H: Clinical effectiveness of quetiapine in children and adolescents with Tourette’s syndrome: a retrospective case-note survey. Clin Drug Investig 2007, 27:123–130.CrossRefPubMed
59.
go back to reference Kenney C, Hunter C, Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007, 22:193–197.CrossRefPubMed Kenney C, Hunter C, Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007, 22:193–197.CrossRefPubMed
60.
go back to reference Kenney C, Hunter C, Davidson A, Jankovic J: Short-term effects of tetrabenazine on chorea associated with Huntington’s disease. Mov Disord 2007, 22:10–13.CrossRefPubMed Kenney C, Hunter C, Davidson A, Jankovic J: Short-term effects of tetrabenazine on chorea associated with Huntington’s disease. Mov Disord 2007, 22:10–13.CrossRefPubMed
61.
go back to reference Porta M, Sassi M, Cavallazzi M, et al.: Tourette’s syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig 2008, 28:443–459.CrossRefPubMed Porta M, Sassi M, Cavallazzi M, et al.: Tourette’s syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig 2008, 28:443–459.CrossRefPubMed
62.•
go back to reference Simpson DM, Blitzer A, Brashear A, et al.: Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699–1706.CrossRefPubMed Simpson DM, Blitzer A, Brashear A, et al.: Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699–1706.CrossRefPubMed
63.
go back to reference Marras C, Andrews D, Sime E, Lang AE: Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001, 56:605–610.PubMed Marras C, Andrews D, Sime E, Lang AE: Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001, 56:605–610.PubMed
64.
go back to reference Kwak CH, Hanna PA, Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol 2000, 57:1190–1193.CrossRefPubMed Kwak CH, Hanna PA, Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol 2000, 57:1190–1193.CrossRefPubMed
65.
go back to reference Rath JJ, Tavy DL, Wertenbroek AA, et al.: Botulinum toxin type A in simple motor tics: short-term and long-term treatment-effects. Parkinsonism Relat Disord 2010, 16:478–481.CrossRefPubMed Rath JJ, Tavy DL, Wertenbroek AA, et al.: Botulinum toxin type A in simple motor tics: short-term and long-term treatment-effects. Parkinsonism Relat Disord 2010, 16:478–481.CrossRefPubMed
66.
go back to reference Porta M, Maggioni G, Ottaviani F, Schindler A: Treatment of phonic tics in patients with Tourette’s syndrome using botulinum toxin type A. Neurol Sci 2004, 24:420–423.CrossRefPubMed Porta M, Maggioni G, Ottaviani F, Schindler A: Treatment of phonic tics in patients with Tourette’s syndrome using botulinum toxin type A. Neurol Sci 2004, 24:420–423.CrossRefPubMed
67.
go back to reference Robertson MM, Schnieden V, Lees AJ: Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 1990, 13:229–235.CrossRefPubMed Robertson MM, Schnieden V, Lees AJ: Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 1990, 13:229–235.CrossRefPubMed
68.
go back to reference Ho CS, Chen HJ, Chiu NC, et al.: Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc 2009, 108:788–793.CrossRefPubMed Ho CS, Chen HJ, Chiu NC, et al.: Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc 2009, 108:788–793.CrossRefPubMed
69.
go back to reference Eggers C, Rothenberger A, Berghaus U: Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 1988, 237:223–229.CrossRefPubMed Eggers C, Rothenberger A, Berghaus U: Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 1988, 237:223–229.CrossRefPubMed
70.
go back to reference Muller-Vahl KR, Schneider U, Prevedel H, et al.: Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003, 64:459–465.CrossRefPubMed Muller-Vahl KR, Schneider U, Prevedel H, et al.: Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003, 64:459–465.CrossRefPubMed
71.
go back to reference Singer HS, Morris C, Grados M: Glutamatergic modulatory therapy for Tourette syndrome. Med Hypotheses 2010, 74:862–867.CrossRefPubMed Singer HS, Morris C, Grados M: Glutamatergic modulatory therapy for Tourette syndrome. Med Hypotheses 2010, 74:862–867.CrossRefPubMed
72.
go back to reference Cubo E, Fernandez Jaen A, Moreno C, et al.: Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study. Clin Ther 2008, 30:182–189.CrossRefPubMed Cubo E, Fernandez Jaen A, Moreno C, et al.: Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study. Clin Ther 2008, 30:182–189.CrossRefPubMed
73.
go back to reference Bortolato M, Muroni A, Marrosu F: Treatment of Tourette’s syndrome with finasteride. Am J Psychiatry 2007, 164:1914–1915.CrossRefPubMed Bortolato M, Muroni A, Marrosu F: Treatment of Tourette’s syndrome with finasteride. Am J Psychiatry 2007, 164:1914–1915.CrossRefPubMed
74.
go back to reference Peterson BS, Zhang H, Anderson GM, Leckman JF: A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette’s syndrome. J Clin Psychopharmacol 1998, 18:324–331.CrossRefPubMed Peterson BS, Zhang H, Anderson GM, Leckman JF: A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette’s syndrome. J Clin Psychopharmacol 1998, 18:324–331.CrossRefPubMed
75.
go back to reference Toren P, Weizman A, Ratner S, et al.: Ondansetron treatment in Tourette’s disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2005, 66:499–503.CrossRefPubMed Toren P, Weizman A, Ratner S, et al.: Ondansetron treatment in Tourette’s disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2005, 66:499–503.CrossRefPubMed
76.
go back to reference Bonnier C, Nassogne MC, Evrard P: Ketanserin treatment of Tourette’s syndrome in children. Am J Psychiatry 1999, 156:1122–1123.PubMed Bonnier C, Nassogne MC, Evrard P: Ketanserin treatment of Tourette’s syndrome in children. Am J Psychiatry 1999, 156:1122–1123.PubMed
77.
go back to reference Perlmutter SJ, Leitman SF, Garvey MA, et al.: Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999, 354:1153–1158.CrossRefPubMed Perlmutter SJ, Leitman SF, Garvey MA, et al.: Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999, 354:1153–1158.CrossRefPubMed
78.
go back to reference Hoekstra PJ, Minderaa RB, Kallenberg CG: Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. J Clin Psychiatry 2004, 65:537–542.CrossRefPubMed Hoekstra PJ, Minderaa RB, Kallenberg CG: Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. J Clin Psychiatry 2004, 65:537–542.CrossRefPubMed
79.
go back to reference Neimat JS, Patil PG, Lozano AM: Novel surgical therapies for Tourette syndrome. J Child Neurol 2006, 21:715–718.CrossRefPubMed Neimat JS, Patil PG, Lozano AM: Novel surgical therapies for Tourette syndrome. J Child Neurol 2006, 21:715–718.CrossRefPubMed
80.•
go back to reference Porta M, Sassi M, Ali F, et al.: Neurosurgical treatment for Gilles de la Tourette syndrome: the Italian perspective. J Psychosom Res 2009, 67:585–590.CrossRefPubMed Porta M, Sassi M, Ali F, et al.: Neurosurgical treatment for Gilles de la Tourette syndrome: the Italian perspective. J Psychosom Res 2009, 67:585–590.CrossRefPubMed
81.
go back to reference Mink JW: Clinical review of DBS for Tourette syndrome. Front Biosci (Elite Ed) 2009, 1:72–76. Mink JW: Clinical review of DBS for Tourette syndrome. Front Biosci (Elite Ed) 2009, 1:72–76.
82.
83.
go back to reference Shields DC, Cheng ML, Flaherty AW, et al.: Microelectrode-guided deep brain stimulation for Tourette syndrome: within-subject comparison of different stimulation sites. Stereotact Funct Neurosurg 2008, 86:87–91.CrossRefPubMed Shields DC, Cheng ML, Flaherty AW, et al.: Microelectrode-guided deep brain stimulation for Tourette syndrome: within-subject comparison of different stimulation sites. Stereotact Funct Neurosurg 2008, 86:87–91.CrossRefPubMed
84.
go back to reference Temel Y, Visser-Vandewalle V: Surgery in Tourette syndrome. Mov Disord 2004, 19:3–14.CrossRef Temel Y, Visser-Vandewalle V: Surgery in Tourette syndrome. Mov Disord 2004, 19:3–14.CrossRef
85.
go back to reference Roessner V, Robatzek M, Knapp G, et al.: First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol 2006, 48:616–621.CrossRefPubMed Roessner V, Robatzek M, Knapp G, et al.: First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol 2006, 48:616–621.CrossRefPubMed
86.
go back to reference Erenberg G: The relationship between Tourette syndrome, attention deficit hyperactivity disorder, and stimulant medication: a critical review. Semin Pediatr Neurol 2005, 12:217–221.CrossRefPubMed Erenberg G: The relationship between Tourette syndrome, attention deficit hyperactivity disorder, and stimulant medication: a critical review. Semin Pediatr Neurol 2005, 12:217–221.CrossRefPubMed
87.
go back to reference Allen AJ, Kurlan RM, Gilbert DL, et al.: Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005, 65:1941–1949.CrossRefPubMed Allen AJ, Kurlan RM, Gilbert DL, et al.: Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005, 65:1941–1949.CrossRefPubMed
88.
go back to reference Singer HS, Brown J, Quaskey S, et al.: The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995, 95:74–81.PubMed Singer HS, Brown J, Quaskey S, et al.: The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995, 95:74–81.PubMed
89.
go back to reference Spencer T, Biederman J, Coffey B, et al.: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2002, 59:649–656.CrossRefPubMed Spencer T, Biederman J, Coffey B, et al.: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2002, 59:649–656.CrossRefPubMed
90.
go back to reference Storch EA, Bjorgvinsson T, Riemann B, et al.: Factors associated with poor response in cognitive-behavioral therapy for pediatric obsessive-compulsive disorder. Bull Menninger Clin 2010, 74:167–185.CrossRefPubMed Storch EA, Bjorgvinsson T, Riemann B, et al.: Factors associated with poor response in cognitive-behavioral therapy for pediatric obsessive-compulsive disorder. Bull Menninger Clin 2010, 74:167–185.CrossRefPubMed
91.
go back to reference Decloedt EH, Stein DJ: Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat 2010, 6:233–242.CrossRefPubMed Decloedt EH, Stein DJ: Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat 2010, 6:233–242.CrossRefPubMed
Metadata
Title
Treatment of Tics and Tourette Syndrome
Author
Harvey S. Singer, MD
Publication date
01-11-2010
Publisher
Current Science Inc.
Published in
Current Treatment Options in Neurology / Issue 6/2010
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-010-0095-4

Other articles of this Issue 6/2010

Current Treatment Options in Neurology 6/2010 Go to the issue